CLOs on the Move

Segerstrom Center for the Arts

www.ocpac.org

 
Segerstrom Center for the Arts is one of the leading providers in Business Services. It is based in Costa Mesa, CA. To find more information about Segerstrom Center for the Arts, please visit www.ocpac.org.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.ocpac.org
  • 600 Town Center Dr
    Costa Mesa, CA USA 92626-1916
  • Phone: 714.556.2121

Executives

Name Title Contact Details

Similar Companies

Vial

Vial is a contract research organization (CRO) reimagining clinical trials to deliver faster, more efficient trial results at dramatically lower costs for biotech sponsors. Our mission is to empower scientists to discover groundbreaking scientific therapeutics that help people live happier, healthier lives. Our modern, intuitive technology platform integrates trial onboarding, patient enrollment, site communication, and data collection processes into one connected system. Vial is building towards a more efficient future for clinical trials. By deploying technology in every step, we are driving efficiencies in speed and cost savings for innovative biotech companies of all sizes.

Wyckoff Family YMCA

The Y makes accessible the support and opportunities that empower people and communities to learn, grow and thrive.

CIK Enterprises

CIK Enterprises is a Indianapolis, IN-based company in the Business Services sector.

Party Pals

Party Pals is a San Diego, CA-based company in the Business Services sector.

AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (NYSEMKT: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi`s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies.